AA
AKBA icon

ALPS Advisors’s Akebia Therapeutics AKBA Stock Holding History

ALPS Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$303K Buy
218,070
+179
+0.1% +$246 ﹤0.01% 976
2025
Q4 		$351K Buy
217,891
+91,830
+73% +$192K ﹤0.01% 924
2025
Q3 		$344K Sell
126,061
-15,603
-11% -$51.9K ﹤0.01% 940
2025
Q2 		$516K Buy
+141,664
New +$389K ﹤0.01% 627
2019
Q2 		– Sell
-282,329
Closed -$2.31M – 879
2019
Q1 		$2.31M Buy
282,329
+61,934
+28% +$425K 0.02% 209
2018
Q4 		$1.22M Buy
220,395
+119,447
+118% +$935K 0.01% 266
2018
Q3 		$891K Buy
100,948
+18,399
+22% +$165K 0.01% 434
2018
Q2 		$824K Buy
82,549
+19,151
+30% +$192K 0.01% 380
2018
Q1 		$604K Buy
63,398
+11,019
+21% +$154K ﹤0.01% 420
2017
Q4 		$779K Buy
52,379
+6,007
+13% +$99.6K 0.01% 308
2017
Q3 		$912K Buy
46,372
+11,323
+32% +$174K 0.01% 258
2017
Q2 		$504K Buy
35,049
+2,079
+6% +$26.4K ﹤0.01% 485
2017
Q1 		$303K Sell
32,970
-3,860
-10% -$37.7K ﹤0.01% 689
2016
Q4 		$383K Sell
36,830
-11,630
-24% -$100K ﹤0.01% 619
2016
Q3 		$439K Sell
48,460
-4,890
-9% -$41.6K ﹤0.01% 368
2016
Q2 		$399K Buy
53,350
+10,728
+25% +$93.6K ﹤0.01% 459
2016
Q1 		$384K Buy
42,622
+2,270
+6% +$18.4K ﹤0.01% 569
2015
Q4 		$521K Sell
40,352
-4,785
-11% -$48.8K 0.01% 388
2015
Q3 		$4.36K Buy
45,137
+16,533
+58% +$152K ﹤0.01% 603
2015
Q2 		$294K Buy
28,604
+18,563
+185% +$158K ﹤0.01% 658
2015
Q1 		$112K Buy
+10,041
New +$107K ﹤0.01% 654

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

ALPS Advisors's AKBA Position: Q1 2026 in Review

ALPS Advisors increased its Akebia Therapeutics (AKBA) stake by 0.08% in Q1 2026, buying an estimated $246 and bringing the position to 218,070 shares worth $303K. The position accounts for ﹤0.01% of the portfolio, ranked #976.

ALPS Advisors first reported a position in AKBA in Q1 2015 and has held it in 21 quarters since. The position peaked at $2.31M in Q1 2019. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • ALPS Advisors held 218,070 shares of Akebia Therapeutics worth $303K as of Q1 2026.
  • ALPS Advisors bought 179 Akebia Therapeutics shares in Q1 2026, an estimated $246.
  • Akebia Therapeutics made up ﹤0.01% of ALPS Advisors's portfolio in Q1 2026, its #976 holding.
  • ALPS Advisors first reported a position in Akebia Therapeutics in Q1 2015 and has held it in 21 quarters since.
  • ALPS Advisors's Akebia Therapeutics position peaked at $2.31M in Q1 2019.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.